[Pfizer Inc.](https://www.pfizer.com)

June 1, 2026

Up to $400,000 USD per project (higher amounts considered case-by-case); max duration 3 years.

Supports research on pediatric pneumococcal disease epidemiology and serotype distribution in Saudi Arabia to inform prevention strategies.

Only organizations in Saudi Arabia are eligible; late applications will not be reviewed.

--- ## Description This opportunity funds research projects that investigate the epidemiology, serotype distribution, genetic evolution, and antibiotic sensitivity of Streptococcus pneumoniae in children under five years old in Saudi Arabia. The grant encourages studies that employ advanced diagnostic and serotyping methods, including retrospective data analysis, use of stored laboratory samples, and/or prospective surveillance. The aim is to address gaps in local knowledge regarding disease burden and serotype diversity following pneumococcal conjugate vaccine (PCV) introduction, ultimately to inform future prevention and public health strategies. Projects should have robust statistical analysis plans and a clear pathway for dissemination of results through conference presentations and peer-reviewed publications. --- ## Due Dates - Submission deadline: June 1, 2026 (by 23:59 Eastern Standard Time) - Anticipated grant award notification: September 2026 - Anticipated project start date: November 2026 - Anticipated project end date: October 2029 **IMPORTANT:** Applications submitted after the due date will not be reviewed. --- ## Funding Amount - Individual projects may request up to $400,000 USD. - Higher budgets may be considered on a case-by-case basis. - The maximum project duration is 3 years. - Award amounts include direct costs, institutional overhead (capped at 28%), and indirect costs. --- ## Eligibility - **Geographic scope:** Saudi Arabia only. - **Applicant organization:** Must be based in Saudi Arabia and legally able to receive funding directly from Pfizer International LLC. - **Principal Investigator (PI):** - Must be based in Saudi Arabia. - Must hold a medical or postdoctoral degree (MD, PhD, or equivalent), advanced nursing degree (BSN with MS/PhD), or a degree in Pharmacy. - Must be an employee or contractor of the requesting organization. - **Eligible applicants:** Only organizations (e.g., hospitals, academic institutions, professional societies) are eligible. Multicenter collaborations are encouraged. - **Ineligible:** Individuals or medical practice groups not affiliated with an eligible organization. - **Other:** All institutions in multicenter projects must have a relevant role; the requesting organization must play a key role. --- ## Application Process - Applications must be submitted via the [Pfizer CyberGrants portal](http://www.cybergrants.com/pfizer/Research). - Register or log in to the portal and select “Start A New Research Grant Application.” - For “Competitive Grant?” select “Yes.” - Primary Area of Interest: “VAV - Pneumococcal - RES.” - Competitive Grant Program Name: “2026 VAC KSA Pneumococcal Disease in Children RES.” - Upload a full proposal (max 15 pages, single-spaced, Calibri 12-point, 1-inch margins) covering: - Goals and objectives - Assessment of need - Target audience - Project design and methods - Innovation - Evaluation and outcomes (including publication plan) - Project timeline - Organization and budget details - Required documents: Project plan or proposal, initial study protocol. - Early-career applicants should include letters of support from mentors/collaborators. --- ## Additional Information - Projects should focus on children under five and may use samples/data from 2023 to 2029. - Both retrospective and prospective surveillance studies are allowed. - Serotyping methods may include conventional (Quellung) or molecular (PCR, whole genome sequencing). - Costs for serotyping (including third-party labs and sample transport) are allowable. - Institutional overhead is capped at 28%. - No funding for capital purchases (equipment/software purchases, infrastructure). - ISR grant requests cannot be for studies already commenced without Pfizer support. - Priority is given to projects with plans for publication or presentation of results. --- ## External Links - [Full RFP and requirements (PDF)](https://cdn.pfizer.com/pfizercom/2026-04/2026-VAC-KSA-PneumococcalDiseaseinChildren-RES.pdf?VersionId=c0BTn8x1suojm2FjMPI8quijUZWOMgVY) - [Pfizer CyberGrants Research Portal](http://www.cybergrants.com/pfizer/Research) - [Pfizer Inc.](https://www.pfizer.com) - [Pfizer Contact Page](https://www.pfizer.com/contact) --- ## Contact Information | Type | Details | |---------------------|---------------------------------------------------------------------------------------------------| | Grant Officer | Neha Singhal (email: [GlobalMedicalGrants@pfizer.com](mailto:GlobalMedicalGrants@pfizer.com)) | | Technical Support | Via CyberGrants portal “Technical Questions” link | | General Inquiries | [Pfizer Contact Page](https://www.pfizer.com/contact) or 1-800-879-3477 |

Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi Arabia

Sign in to see full grant listing